[Seite 105↓]


Aebi, S., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland, C. R., Koi, M., Fishel, R., Howell, S. B. (1996). Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56, 3087-3090.

Allen, J. D., Brinkhuis, R. F., Wijnholds, J, Schinkel, A. H. (1999 ). The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 59, 4237-4241.

Arts, H. J. G., Katsaros, D., de Vries, E. G. E., Massobrio, M., Genta, F., Danese, S., Arisio, R., Scheper, R. J., Kool, M., Scheffer, G. L., Willemse, P. H. B., van der Zee, A. G. J., Suurmeijer, A. J. H. (1999). Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin. Cancer. Res. 5, 2798-2805.

Ban, N., Takahashi, Y., Takayama, T., Kura, T., Katahira, T., Sakamaki, S., Niitsu, Y. (1996). Transfection of glutathione S-transferase (GST)- π antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, mephalan, and etoposide. Cancer Res. 56, 3577-3582.

Bauer, B. E., Wolfger, H., Kuchler, K. (1999). Inventory and function of yeast ABC proteins: about sex, stress, pleiotropic drug and heavy metal resistance. Biochim. Biophys. Acta 1461, 217-236.

Becker, N., Wahrendorf, J. (1998). Krebsatlas der Bundesrepublik Deutschland 1981-1990, 3. völlig neu bearbeitete Auflage, DKFZ Heidelberg.

Bergman, A. M., Giaccone, G., van Moorsel, C. J. A., Mauritz, R., Noordhuis, P., Pinedo, H. M., Peters, G. J. (2000). Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Eur. J. Cancer 36, 1974-1983.

Bertrand, E., Pictet, R., Grange, T. (1994). Can hammerhead ribozymes be efficient tools to inactivate gene function? Nucleic Acids Res. 22, 293-300.

Bettinger, T., Read, M. L. (2001). Recent developments in RNA-based strategies for cancer gene therapy. Curr. Opin. Mol. Ther. 3, 116-124.

Broeks, A., Gerrard, B., Allikmets, R., Dean, M., Plasterk, R. H. A. (1996). Homologues of the human multidrug resistance genes MRP and MDR contribute to heavy metal resistance in the soil nematode Caenorhabditis elegans. EMBO J. 15, 6132-6143.

Brown, R., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P., van der Zee, A. G. J., Anthoney, D. A. (1997). hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15, 45-52.

[Seite 106↓]

Büchler, M., König, J., Brom, M., Kartenbeck, J., Spring, H., Horie, T., Keppler, D. (1996). cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMRP, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J. Biol. Chem. 271, 15091-15098.

Camplejohn, R. S., Rutherford, J. (2001). P53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours. Cell Prolif. 34, 1-14.

Chen, Z., Mutoh, M., Sumizawa, T., Furukawa, T., Haraguchi, M., Tani, A., Saijo, N., Kondo, T., Akiyama, S. (1998). An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells. Exp. Cell Res . 240, 312-320.

Chen, Z., Kawabe, T., Ono, M., Aoki, S., Sumizawa, T., Furukawa, T., Uchiumi, T., Wada, M., Kuwano, M., Akiyama, S. (1999). Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol. Pharmacol. 56, 1219-1228.

Chugani, D. C., Rome, L. H., Kedersha, N. L. (1993). Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J. Cell Sci. 106, 23-9.

Codegoni, A. M., Broggini, M., Pitelli, M. R., Pantarotto, M., Torri, V., Mangioni, C., D'Incalici, M. (1997). Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol. Oncol. 65, 130-137.

Cole, S. P. C., Bhardwaj, G., Gerlach, J. H. et al. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650-1654.

Cole, S. P. C., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., Deeley, R. G. (1994). Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 53, 5225-5232.

Crul, M., Schellens, J. H. M., Beijnen, J. H., Maliepaard, M. (1997). Cisplatin resistance and DNA repair. Cancer Treatment Rev. 23, 341-366.

Cui, Y., König, J., Buchholz, U., Spring, H., Leier, I., Keppler, D. (1999). Drug resistance and ATP-dependent conjugate transport mediated by the atypical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55, 929-937.

Dahm, S. C., Uhlenbeck, O. C. (1991). Role of divalent metal ions in the hammerhead RNA. Biochemistry 30, 9464-9469.

Dean, M., Hamon, Y., Chimini, G. (2001). The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42, 1007-1017.

Debatin, K. (2000). Activation of apoptosis pathways by anticancer treatment. Toxicol. Letters 112-113, 41-48.

Dijkstra, M., Havinga, R., Vonk, R. J., Kuipers, F. (1996). Bile secretion of cadmium, silver, zink, and copper in the rat. involvement of various transport systems. Life Sci. 59, 1237-1246.

[Seite 107↓]

Di Marco, A., Gaetani, M., Dorigotti, L. et al. (1963). Studi sperimentali sull’attivita antineoplastica del nuovo antibiotico daunomycina. Tumori 49, 203-217

Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., Ross, D. D. (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 95 , 15665-15667 .

Drummond, J. T., Anthoney, A., Brown, R., Modrich, P. (1996). Cisplatin and adriamycin resistance are associated with MutL α and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem. 271, 19645-19448.

Dubost, M., Ganter, P., Maral, R. et al. (1963). Un nouvel antibiotique á propriétés cytostatiques: la rubidomycine. C. R. Academie des Sciences (Paris) 257, 1813-1815.

Dunton, C. J. (1997). New options for the treatment of advanced ovarian cancer. Semin. Oncol. 24, S5.2-S5.11.

Efferth, T. (2001). The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr. Mol. Med. 1, 45-65.

Eva, A., Robbins, K. C., Andersen, P. R., Srinivasan, A., Tronick, S. R., Reddy, E. P., Ellmore, N. W., Galen, A. T., Lautenberger, J. T., Papas, T. S., Westin, E. H., Wong-Staal, F., Gallo, R. C., Aaronson, S. T. (1982). Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. Nature 295, 116-119

Fink, D., Nebel, S., Norris, P. S., Baergen, R. N., Wilczynski, S. P., Costa, M. J., Haas, M., Cannistra, S. A., Howell, S. B. (1998). Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int. J. Cancer 77, 741-746.

Fogh, J., Bean, M. A., Brüggen, J., Fogh, H., Fogh, J. M., Hammar, S. P., Kodera, Y., Loveless, J. D., Sorg, C., Wright, W. C. (1978). Comparison of a human tumor cell line before and after growth in the nude mouse. In: Fogh, J., Giovanella, B., editors. The Nude mouse in experimental and clinical research. Academic Press, New York: 215-234.

Forster, A. C., Symons, R. H. (1987). Self-cleavage of virusoid RNA is performed by the proposed 55-nucleotide active site. Cell 50, 9-16.

Funato, T., Ishii, T., Kanabe, M., Scanlon, K. J., Sasaki, T. (1997). Reversal of cisplatin resistance in vivo by an anti-fos ribozyme. in vivo 11, 217-220.

Funato, T., Ishii, T., Kambe, M., Scanlon, K. J., Sasaki, T. (2000). Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human cancer cells. Cancer Gene Ther. 7, 496-500.

Giaccone, G. (2000). Clinical perspectives on platinum resistance. Drugs 59, Suppl. 4, 9-17.

Gonzalez, V. M., Fuertes, M. A., Alonso, C., Perez, J. M. (2001). Is cisplatin-induced cell death always produced by apoptosis? Mol. Pharmacol. 59, 657-663.

Gottesman, M. M. (2002). Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627.

[Seite 108↓]

Grant, C. E., Valdimarsson, G., Hipfner, D. R. et al.(1994). Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 54, 357-361.

Hande, K. R. (1998). Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta 1400, 173-184.

Harris, M. J., Kuwano, M., Webb, M., Board, P. G. (2001). Identification of the apical membrane-targeting signal of the multidrug resistance-associated protein 2 (MRP2/cMOAT). J. Biol. Chem. 276, 20876-20881.

Harvard Report on Cancer Prevention (1996). Vol. 1: Causes of human cancer. Cancer Causes Control Suppl. 1, S55-S58

Haselhoff, J., Gerlach, W. L. (1988). Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334, 585-591.

Hawn, M. T., Umar, A., Carethers, J. M., Marra, G., Kunkel, T. A., Boland, C. R., Koi, M. (1995). Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res. 55, 3721-3725.

Heidenreich, O., Eckstein, F. (1992). Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1. J. Biol. Chem. 267, 1904-1909.

Heidenreich, O., Benseler, F., Fahrenholz, A., Eckstein, F. (1994). High activity and stability of hammerhead ribozymes containing 2’-modified pyrimidine nucleosides and phosphothioates. J. Biol. Chem. 269, 2131-2138.

Heim, M. E., Fritze, D., Ho, A. D. et al. (1987). Phase-III-Studie zur Chemotherapie niedrig-maligner Non-Hodgkin-Lymphome: Vergleich einer Vincristin- mit einer Vindesin-Kombinations-Chemotherapie. Onkologie 10, 345-348.

Helmbach, H., Kern, M. A., Rossman, E., Renz, K., Kissel, C., Gschwedt, B., Schadendorf, D. (2002). Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J. Invest. Dermatol. 118, 923-932.

Hendry, P., McCall, M. J., Santiago, F. S., Jennings, P. A. (1995). In vitro activity of minimised hammerhead ribozymes. Nucleic Acids Res. 23, 3922-3927.

Hendry, P., McCall, M. J. (1995). A comparison of the in vitro activity of DNA-armed and all-RNA hammerhead ribozymes. Nucleic Acids Res. 23, 3928-3936.

Hendry, O., McCall, M. J., Lockett, T. J. (1997). Characterizing ribozyme cleavage reactions. Methods Mol. Biol. 74, 221-229.

Hertel, K. J., Pardi, A., Uhlenbeck, O. C., Koizumi, M., Ohtsuka, E., Uesugi, S., Cedergren, R., Eckstein, F., Gerlach, W. L., Hodgson, R., Symons, R. H. (1992). Numbering system for the hammerhead. Nucl. Acids Res. 20, 3252.

[Seite 109↓]

Hertel, K. J., Herschlag, D., Uhlenbeck, O. C. (1994). A kinetic and thermodynamic framework for the hammerhead ribozyme reaction. Biochemistry 33, 2131-2138.

Holm, P. S., Scanlon, K. J., Dietel, M. (1994). Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br. J. Cancer 70, 239-243.

Holm, P. S., Dietel, M., Krupp, G. (1995). Similar cleavage efficiencies of an oligoribonucleotide substrate and an mdr1 mRNA segment by a hammerhead ribozyme. Gene 167, 221.

Hooijberg, J. H., Broxterman, H. J., Kool, M., Assaraf, Y. G., Peters, G. J., Noordhuis, P., Scheper, R. J., Borst, P., Pinedo, H. M., Jansen, G. (1999). Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59, 2532-2535.

Iida, T., Kijima, H., Urata, Y., Goto, S., Ihara, Y., Oka, M., Kohno, S., Scanlon, K. J., Kondo, T. (2001). Hammerhead ribozyme against γ -glutamycysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Therapy 8, 803-814.

Ishikawa, T. Ali-Osman, F. (1993). Glutathion-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. J. Biol. Chem. 268, 20116-20125.

Ishikawa, T., Li, Z., Lu, Y., Rea, P. A. (1997). The GS-X pump in plant, yeast, and animal cells: structure, function, and gene expression. Biosci. Rep. 17, 189-207.

Ito, K., Suzuki, H., Hirohashi, T., Kume, K., Shimizu, T., Sugiyama, Y. (1997). Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am. J. Physiol. 272, G16-G22.

Itoda, M., Saito, Y., Soyama, A., Saeki, M., Murayama, N., Ishida, S., Sai, K., Nagano, M., Suzuki, H., Sugiyama, Y., Ozawa, S., Sawada, J. J. (2002). Polymorphisms in ther ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5'-untranslated region and exon 28. Drug Metab. Dispos. 30, 363-364.

Izquierdo, M. A., Scheffer, G. L., Flens, M. J., Schroeijer, A. B., van der Valk, P., Scheper, R. J. (1996). Major vault protein LRP-related multidrug resistance. Eur. J. Cancer 32A, 979-984.

Jones, N. A., Turner, J., McIlwrath, A. J., Brown, R., Dive, C. (1998). Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between Bax and Bak up-regulation and the functional status of p53. Mol. Pharmacol. 53, 819-826.

Jordan, P., Carmo-Fonseca, M. (2000). Molecular mechanisms involved in cisplatin cytotoxicity. Cell. Mol. Life Sci. 57, 1229-1235.

Juliano, R. L., Ling, V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochem. Biophys. Acta 455, 152-162.

[Seite 110↓]

Kala, S. V., Neely, M. W., Kala, G., Prater, C. I., Atwood, D. W., Rice, J. S., Lieberman, M. W. (2000). The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J. Biol. Chem. 275, 33404-33408.

Kamisako, T., Kobayashi, Y., Takeuchi, K., Ishihara, T., Higuchi, K., Tanaka, Y., Gabazza, E. C., Adachi, Y. (2000). Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance. J. Gastroenterol. 35, 659-664.

Kaufmann, S. H., Earnshaw. (2000). Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 256, 42-49.

Kawabe, T., Chen, Z., Wada, M., Uchiumi, T., Ono, M., Akiyama, S., Kuwano, M. (1999). Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Letters 456, 327-331.

Kellner, U., Hutchinson, L., Seidel, A., Lage, H., Danks, M. K., Dietel, M., Kaufmann, S. H. (1997). Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Int. J. Cancer 71, 817-824.

Keppler, D., König, J. (1997). Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J. 11, 509-516.

Keppler, D., Leier, I., Jedlitschky, G. (1997). Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol. Chem. 378, 787-791.

Keppler, D. (1999). Export pumps for glutatione S-conjugates. Free Rad. Biol. Med. 27, 985-991.

Keppler, D., Cui, Y., Konig, J., Leier, L., Nies, A. (1999). Export pumps for anionic conjugates encoded by MRP genes. Advan. Enzyme Regul. 39, 237-246.

Kern, M. A., Helmbach, H., Artuc, M., Karmann, D., Jurgovsky, K., Schadendorf, D. (1997). Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposid: modulation of proto-oncogene expression. Anticancer Res. 17, 4359-4370.

Kigawa, J., Minagawa, Y., Kanamori, Y., Itamochi, H., Cheng, X., Okada, M., Oishi, T., Terakawa, N. (1998). Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer. Cancer 82, 697-702.

Kitazono, M., Sumizawa, T., Takebayashi, Y., Chen, Z., Furukawa, T., Nagayama, S., Tani, A., Takao, Sonshin, Aikou, T., Akiyama, S. (1999). Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J. Natl. Cancer Inst. 91, 1647-1653.

Kobayashi, H., Kim, N., Halatsch, M. E., Ohnuma, T. (1994). Specificity of ribozyme designed for mutated DHFR mRNA. Biochem. Pharmacol. 47, 1607-1613.

[Seite 111↓]

Koike, K., Kawabe, T., Tanaka, T., Toh, S., Uchiumi, T., Wada, M., Akiyama, S., Ono, M., Kuwano, M. (1997). A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 57, 5475-5479.

Kool, M., de Haas, M., Scheffer, G. L., Scheper, R. J., van Eijk, M. J. T., Juijn, J. A., Baas, F., Borst, P. (1997). Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57, 3537-3547.

Kowalski, P., Wichert, A., Holm, P. S., Dietel, M., Lage, H. (2001). Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther. 8, 185-192.

Kowalski, P., Stein, U., Scheffer, G. L., Lage, H. (2002). Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC-transporter BCRP/MXR/ABCG2. Cancer Gene Ther. 9: 579-586.

König, J., Nies, A. T., Cui, Y., Leier, I., Keppler, D. (1999). Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461, 377-394.

Kurokawa, H., Ishida, T., Nishio, K., Arioka, H., Sata, M., Fukumoto, H., Miura, M., Saijo, N. (1995). gamma-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. Biochem. Biophys. Res. Commun. 216, 258-264.

Lage, H., Christmann, M., Kern, M. A., Dietel, M., Pick, M., Kaina, B., Schadendorf, D. (1999). Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Int. J. Cancer 80, 744-750.

Lage, H., Dietel, M. (1999). Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J. Cancer Res. Clin. Oncol . 125, 156-165.

Lage, H. (1999). Atypische Multidrug-Resistenz. Arzneimitteltherapie 17, 39-44.

Lage, H., Perlitz, C., Abele, R., Tampe, R., Dietel, M., Schadendorf, D., Sinha, P. (2001). Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone. FEBS Letters 503, 179-184.

Lage, H., Helmbach, H., Grottke, C., Dietel, M., Schadendorf, D. (2001b). DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. FEBS Letters 494, 54-59.

Lee, N. S., Bertrand, E., Rosel, J. J. (1997). Enhancement of ribozyme function by RNA binding protein. Ribozyme Protocols, Methods in molecular biology 74, Humana Press, Totowa, New Jersey

Levesque, M. A., Kataros, D., Yu, H. et al.(1995). Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75, 1327-1338.

[Seite 112↓]

Lewin, A. S., Hauswirth, W. W. (2001). Ribozyme gene therapy: application for molecular medicine. Trends Mol. Med. 7, 221-228.

Lieber, A., Strauss, M. (1995). Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol. Cell. Biol. 15, 540-551.

Lincke, C. R., van der Blick, A. M., Schuurhuis, G. J., van der Velde-Koerts, T. Smit, J. J., Borst, P. (1990). Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Cancer Res. 50, 1779-1785.

Litman, T., Druley, T. E., Stein, W. D., Bates, S. E. (2001). From MDR to MXR: new understandings of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci. 58, 931-959.

Liu, J., Chen, H., Miller, D. S., Saavedra, J. E., Keefer, L. K., Johnson, D. R., Klaassen, C. D., Waalkes, M. P. (2001). Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol. Pharmacol . 60, 302-309.

Lu, X., Errington, J., Curtin, N. J., Lunec, J., Newell, D. R. (2001). The impact of p53 status on cellular sensitivity to antifolate drugs. Clin. Cancer Res. 7, 2114-2123.

Lyngstadaas, S. P. (2001). Synthetic hammerhead ribozymes as tools in gene expression. Crit. Rev. Oral Biol. Med. 12, 469-478.

Manetta, A., Blessing, J. A., Hurteau, J. A. (1998). Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group. Gynecol. Oncol. 68, 45-46

Materna, V., Holm, P. S., Dietel, M., Lage, H. (2001). Kinetic characterization of ribozymes directed against the cisplatin resistance-associated ABC transporter cMOAT/MRP2/ABCC2. Cancer Gene Ther. 8, 1-9.

Minemura, M., Tanimura, H., Tabor, E. (1999). Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int. J. Oncol. 15, 559-563.

Mor-Cohen, R., Zivelin, A., Rosenberg, N., Shani, M., Muallem, S., Seligsohn, U. (2001). Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J. Biol. Chem. 276, 36923-36930.

Nagata, J., Kijima, H., Hatanaka, H., Asai, S., Miyachi, H., Takagi, A., Miwa, T., Mine, T., Yamazaki, H., Nakamura, M., Kondo, T., Scanlon, K. J., Ueyama, Y. (2001). Reversal of cisplatin and multidrug resistance by ribozyme-mediated glutathione suppression. Biochem. Biophys. Res. Commun. 286, 406-413.

Narasaki, F., Oka, M., Nakano, R., Ikeda, K., Fukuda, M., Nakamura, T., Soda, H., Nakagawa, M., Kuwano, M., Kohno, S. (1997). Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells. Biochem. Biophys. Res. Commun. 240, 606-611.

[Seite 113↓]

Nies, A. T., König, J., Pfannschmidt, M., Klar, E., Hofmann, W. J., Keppler, D. (2001). Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int. J. Cancer 94, 492-499.

Oguri, T., Fujiwara, Y., Isobe, T., Katoh, O., Watanabe, H., Yamakido, M. (1998). Expression of gamma-glutamylcysteine synthetase (gamma-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs. Br. J. Cancer 77, 1089-1096.

Oguri, T., Fujiwara, Y., Miyazaki, M., Takahashi, T., Kurata, T., Yokozaki, M., Ohashi, N., Isobe, T., Katoh, O., Yamakido, M. (1999). Induction of gamma-glutamylcysteine synthase gene expression by platinum drugs in peripheral mononuclear cells of lung cancer patients. Ann. Oncol. 10, 455-460.

Ozols, R. F., Young, R. C. (1991). Chemotherapy of ovarian cancer. Semin. Oncol. 18, 222

Parekh, H., Simpkins, H. (1996). Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells. Cancer Chemother. Pharmacol. 37, 457-462.

Parker, S. L., Tong, T., Bolden, S., Wingo, P. A. (1997). Cancer statistics 1997. CA Cancer J. Clin. 47, 5-27.

Paulusma, C. C., Bosma, P. J., Zaman, G. J. R., Bakker, C. T. M., Otter, M., Scheffer, G. L., Scheper, R. J., Borst, P., Oude-Elferink, R. P. J. (1996). Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271, 1126-1128.

Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., Zunino, F. (1996). Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 56, 556-562.

Perez, R. P., Godwin, A. K., Handel, L. M., Hamilton, T. C. (1993). A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur. J. Cancer 29A, 395-399.

Pratt, W. B., Ruddon, R. W., Ensminger, W. D., Maybaum, J. (1994). The Anticancer Drugs. 2nd edition, Oxford University Press, New York, Oxford.

Pieken, W. A., Olsen, D. B., Benseler, F., Aurup, H., Eckstein, F. (1991). Structure-function relationship of hammerhead ribozymes as probes by 2'-modifications. Nucl. Acids Symp. Ser. 24, 51-53.

Righetti, S. C., Della Torre, G., Piloti, S., Menard, S., Ottone, F., Colnaghi, M. I., Pierotti, M. A., Lavarino, C., Cornarotti, M., Oriana, S., Bohm, S., Bresciani, G. L., Spatti, F., Zunino F. (1996). A comparative study of p53 mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 56, 689-693.

[Seite 114↓]

Rocchi, E., Khodjakov, A., Volk, E. L., Yang, C., Litman, T., Bates, S. E., Schneider, E. (2000). The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem. Biophys. Res. Commun. 271, 42-46.

Rodriguez-Galindo, C., Radomski, K., Stewart, C. F., Furman, W., Santana, V. M., Houghton, P. J. (2000). Clinical use of topoisomerase I inhibitors in anticancer treatment. Med. Pediatr. Oncol. 35, 385-402.

Rose, P. G., Blessing, J. A., Mayer, A. R., Homesley, H. D. (1998). Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oncol. 16, 405-410.

Rosenberg, B., van Camp, L., Krigas, T. (1965). Inhibition of cell devision in Escherichia coli by electrolysis products from a platinum electrode. Nature 205, 698-699.

Ross, W., Rowe, T., Glisson, B. et al.(1984). Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res. 44: 5857-5860.

Ross, D. D., Yang, W., Abruzzo, L. V., Dalton, W. S., Schneider, E., Lage, H., Dietel, M., Greenberger, L., Cole, S. P. C., Doyle, L. A. (1999). Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst. 91, 429-433.

Roy, G., Horton, J. K., Roy, R., Denning, T., Mitra, S., Boldogh, I. (2000). Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins. Oncogene 19, 141-150.

Sambrook, J., Russell, D. W (2001). Molecular cloning. A laboratory manual. Vol. 1-3, 3rd edition, Cold Spring Harbor Lab press. Cold Spring Harbor, New York.

Sen, D., Geyer, C. R. (1998). DNA enzymes. Curr. Opin. Chem. Biol. 2, 680-687.

Senchenkov, A., Litvak, D., A., Cabot, M. C. (2001). Tageting ceramid metabolism - a strategy for overcoming drug resistance. J. Natl. Cancer. Inst. 93, 347-357.

Sharp, S. Y., Smith, V., Hobbs, S., Kelland, L. R. (1998). Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines. Br. J. Cancer 78, 175-180.

Siddik, Z. H., Mims, B., Lozano, G., Thai, G. (1998). Independent pathway of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res. 58, 698-703.

Soini, Y., Järvinen, K., Kaarteenaho-Wiik, R., Kinnula, V. (2001). The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma. Ann. Oncol. 12, 1239-1245.

Stein, C. A., Cheng, Y. (1993). Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 261, 1004-1011.

[Seite 115↓]

Stöckel, B., König, J., Nies, A. T., Cui, Y., Brom, M., Keppler, D. (2000). Characterization of the 5'-flanking region of the human multidrug resistance protein 2 (MRP2) gene and its regulation in comparison with the multidrug resistance protein 3 (MRP3) gene. Eur. J. Biochem. 267, 1347-1358.

Strange, R. C., Jones, P. W., Fryer, A. A. (2000). Glutathione S-transferase: genetics and role in toxicology. Toxicol. Lett. 112-113, 357-363.

Sugawara, N., Lai, Y., Arizono, K., Kitajima, T., Inoue, H. (1997). Lack of biliary ecreation of Cd linked to an inherent defect of the canalicular isoform of multidrug resistance protein (cMrp) does not abnormally stimulate accumulation of Cd in the Esai hyperbilirubinemic (EHB) rat liver. Arch. Toxicol. 71, 336-339.

Sugawara, N., Lai, Y., Sugaware, C., Arizono, K. (1998). Decreased hepatobiliary secretion of inorganic mercury, its deposition and toxicity in the Eisai hyperbilirubinemic rat with no hepatic canalicular organic anion transporter. Toxicology 126, 23-31.

Tanaka, T., Uchiumi, T., Hinoshita, E., Inokuchi, A., Toh, S., Wada, M., Takano, H., Kohno, K., Kuwano, M. (1999). The human multidrug resistance protein 2 gene: functional characterization of the 5'-flanking region and expression in hepatic cells. Hepatology 30, 1507-1512.

Taniguchi, K., Wada, M., Kohno, K., Nakamura, T., Kawabe, T., Kawakami, M., Kagotani, K., Okumura, K., Akiyama, S., Kuwano, M. (1996). A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56, 4124-4129.

Theodoulou, F. L. (2000). Plant ABC transporters. Biochim. Biophys. Acta 1465, 79-103.

Tietze, F. (1969). Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Analytical Biochem. 27, 502-522.

Toh, S., Wada, M., Uchiumi, T., Inokuchi, A., Makino, Y., Horie, Y., Adachi, Y., Sakisaka, S., Kuwano, M. (1999). Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am. J. Hum. Genet. 64, 739-746.

Trimmer, E. E., Essigmann, J. M. (1999). Cisplatin. Essays Biochem. 34, 191-211.

Tsujii, H., König, J., Rost, D., Stöckel, B., Leuschner, U., Keppler, D. (1999). Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. Gastroenterol. 117, 653-660.

van der Zee, A. G., Hollema, H., Suurmeijer, A. J. et al. (1995). Value of P-glycoprotein, glutathion S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinoma. J. Clin. Oncol. 13, 70-78.

Wichert, A., Holm, P. S., Dietel, M., Lage, H. (1999). Selection of a high activity ribozyme against cytostatic drug resistance-associated glypican-3 using an in vitro assay containing total tumor RNA. Cancer Gene Ther. 6, 263-270.

[Seite 116↓]

Willet, W. C. (1995) Diet, nutrition and avoidable cancer. Environmental Health Perspectives 103 (Suppl. 8), S165-S170.

Williams, S. D., Birch, R., Einhorn, L. H. et al.(1987). Dissiminated germ cell tumor: chemotherapy with cisplatin plus bleomycin plus either vinblastine or etoposid. A trial of the Southeastern Cancer Study Group. N. Engl. J. Med. 316, 1435-1440.

Yao, K., Godwin, A. K., Johnson, S. W., Ozols, R. F., O'Dwyer, P. J., Hamilton, T. C. (1995). Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cislatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res. 55, 4367-4374.

Young, L. C., Campling, B. G., Voskoglou-Nomikos, T., Cole, S. P. C., Deeley, R. G., Gerlach, J. H. (1999). Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin. Cancer Res. 5, 673-680

Young, J., Holland, I. B. (1999). ABC transporters: bacterial exporters – revisited five years on. Biochim. Biophys. Acta 1461, 177-200.

Zanetta, G., Monico, S. L., Gabriele, A., Miceli, D., Mangioni, C. (1996). Chemotherapy with doxorubicin, etoposide and cyclophosphamide (DEC) in ovarian cancer persistent after platinum-based treatment. Eur. J. Cancer 32A, 178-179.

Zarrinkar, P. P., Williamson, J. R. (1994). Kinetic intermediates in RNA folding. Science 265 (5174), 918-924.

Zeller und zur Hausen (1995). Onkologie: Grundlagen, Diagnostik, Therapie, Entwicklungen. Loseblattsammlung.

Zimniak, P. (1993). Dubin-Johnson and Rotor syndromes: molecular basis and pathogenesis. Semin. Liver. Dis. 13, 248-260.

Zuker, M., Stiegler, P. (1981) Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information. Nucleic Acids Res. 9, 133-148.

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am: